REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 156 filers reported holding REVANCE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $36,000 | -16.3% | 2,597 | +17.4% | 0.00% | – |
| Q1 2022 | $43,000 | 0.0% | 2,213 | -16.9% | 0.00% | – |
| Q4 2021 | $43,000 | -17.3% | 2,662 | +42.0% | 0.00% | – |
| Q3 2021 | $52,000 | -7.1% | 1,874 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $56,000 | -15.2% | 1,874 | -21.1% | 0.00% | 0.0% |
| Q1 2021 | $66,000 | +34.7% | 2,374 | +36.3% | 0.00% | 0.0% |
| Q4 2020 | $49,000 | +11.4% | 1,742 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $44,000 | 0.0% | 1,742 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $44,000 | +1366.7% | 1,742 | +771.0% | 0.00% | – |
| Q3 2019 | $3,000 | 0.0% | 200 | 0.0% | 0.00% | – |
| Q2 2019 | $3,000 | 0.0% | 200 | 0.0% | 0.00% | – |
| Q1 2019 | $3,000 | -25.0% | 200 | 0.0% | 0.00% | – |
| Q4 2018 | $4,000 | -20.0% | 200 | 0.0% | 0.00% | – |
| Q3 2018 | $5,000 | 0.0% | 200 | 0.0% | 0.00% | – |
| Q2 2018 | $5,000 | -16.7% | 200 | 0.0% | 0.00% | – |
| Q1 2018 | $6,000 | -14.3% | 200 | 0.0% | 0.00% | – |
| Q4 2017 | $7,000 | +16.7% | 200 | 0.0% | 0.00% | – |
| Q3 2017 | $6,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NQ HCIF GP, Ltd. | 3,096,650 | $52,457,000 | 100.00% |
| Essex Woodlands Management, Inc. | 4,592,047 | $77,789,000 | 24.28% |
| Rhenman & Partners Asset Management AB | 126,574 | $2,144,000 | 0.62% |
| Polar Capital LLP | 1,107,272 | $18,756,000 | 0.37% |
| ArrowMark Colorado Holdings LLC | 787,923 | $13,347,000 | 0.34% |
| Lombard Odier Asset Management (USA) Corp | 250,605 | $4,245,000 | 0.29% |
| Visium Asset Management, LP | 1,000,000 | $16,940,000 | 0.24% |
| C Partners Holding GmbH | 24,000 | $407,000 | 0.13% |
| NOTTINGHAM ADVISORS, INC. | 23,018 | $390,000 | 0.10% |
| WALL STREET ASSOCIATES | 57,330 | $971,000 | 0.09% |